MYEOV and familial pancreatic carcinoma: It was found that high expressed MYEOV was significantly associated with shorter survival in pancreatic cancer patients, both in OS (p = 2.3 × 10−6), DSS (p = 3.5 × 10−7), DFI (p = 0.063), and PFS (p = 1.7 × 10−4) (Figure 1E–H).